T1	Condition 13 21	pregnant
T2	Condition 30 47	pregnancy outcome
T3	Temporal 48 82	within 3 months prior to enrolment
T4	Reference_point 73 82	enrolment
R1	multi Arg1:T3 Arg2:T4	
*	OR T1 T2
T6	Qualifier 25 29	last
T7	Temporal 25 29	last
R3	Has_qualifier Arg1:T2 Arg2:T6	
R4	multi Arg1:T6 Arg2:T7	
T8	Condition 97 111	breast-feeding
T9	Temporal 87 96	Currently
T10	Temporal 3 12	Currently
R2	Has_temporal Arg1:T2 Arg2:T3	
R5	Has_temporal Arg1:T1 Arg2:T10	
R6	Has_temporal Arg1:T8 Arg2:T9	
T5	Context_Error 116 190	Participated in any other research study within 60 days prior to screening
T11	Context_Error 195 243	Previously participated in any HIV vaccine study
T12	Condition 258 279	urogenital infections
T13	Qualifier 248 257	Untreated
R7	Has_qualifier Arg1:T12 Arg2:T13	
T14	Condition 288 299	symptomatic
T15	Condition 303 315	asymptomatic
*	OR T15 T14
T16	Scope 288 315	symptomatic or asymptomatic
R8	Has_scope Arg1:T12 Arg2:T16	
T17	Temporal 317 351	within 2 weeks prior to enrollment
T18	Reference_point 341 351	enrollment
R9	Has_index Arg1:T17 Arg2:T18	
R10	Has_temporal Arg1:T12 Arg2:T17	
T19	Condition 368 406	abnormal physical finding on the vulva
T20	Condition 368 400;408 421	abnormal physical finding on the vaginal walls
T21	Condition 368 400;425 431	abnormal physical finding on the cervix
*	OR T21 T20 T19
T22	Procedure 446 466	speculum examination
T23	Procedure 439 445;455 466	pelvic examination
*	OR T23 T22 T24
T24	Procedure 474 484	colposcopy
T25	Scope 439 484	pelvic/speculum examination and/or colposcopy
T26	Scope 368 431	abnormal physical finding on the vulva, vaginal walls or cervix
R11	causal Arg1:T26 Arg2:T25	
T27	Condition 512 522;534 542	urogenital prolapse
T28	Condition 526 542	uterine prolapse
T29	Condition 556 572	vaginal bleeding
T30	Qualifier 544 555	undiagnosed
R12	Has_qualifier Arg1:T29 Arg2:T30	
T31	Condition 574 594	urethral obstruction
*	OR T27 T28
T32	Qualifier 500 511	significant
T33	Observation 489 496	History
T34	Scope 512 542	urogenital or uterine prolapse
T35	Subjective_judgement 500 511	significant
R13	Has_qualifier Arg1:T34 Arg2:T32	
R14	Has_temporal Arg1:T34 Arg2:T33	
*	OR T34 T29 T31
T36	Measurement 599 608	Pap smear
T37	Temporal 616 628	at screening
T38	Value 634 654	requires cryotherapy
T39	Value 634 642;656 662	requires biopsy
T40	Value 634 642;664 673	requires treatment
T41	Procedure 643 654	cryotherapy
T42	Procedure 656 662	biopsy
T43	Procedure 664 673	treatment
T44	Value 634 642;705 723	requires further evaluation
T45	Procedure 705 723	further evaluation
*	OR T38 T39 T40 T44
T46	Scope 634 673;702 723	requires cryotherapy, biopsy, treatment or further evaluation
R15	Has_scope Arg1:T36 Arg2:T46	
R16	Has_temporal Arg1:T36 Arg2:T37	
R17	multi Arg1:T38 Arg2:T41	
R18	multi Arg1:T39 Arg2:T42	
R19	multi Arg1:T40 Arg2:T43	
R20	multi Arg1:T44 Arg2:T45	
T47	Condition 794 816	laboratory abnormality
T48	Condition 783 793;805 816	urinalysis abnormality
T49	Condition 770 779;805 816	chemistry abnormality
T50	Condition 757 768;805 816	haematology abnormality
T51	Value 732 747	Grade 2, 3 or 4
T52	Temporal 748 756	baseline
T53	Measurement 834 877	DAIDS Table for Grading Adverse Experiences
*	OR T48 T49 T50
R21	Has_temporal Arg1:T53 Arg2:T52	
R22	Has_value Arg1:T53 Arg2:T51	
T54	Procedure 757 768	haematology
T55	Procedure 770 779	chemistry
T56	Procedure 783 793	urinalysis
T57	Procedure 794 804	laboratory
R23	multi Arg1:T50 Arg2:T54	
R24	multi Arg1:T49 Arg2:T55	
R25	multi Arg1:T48 Arg2:T56	
R26	multi Arg1:T47 Arg2:T57	
T58	Condition 917 936	bleeding per vagina
T59	Qualifier 896 907	undiagnosed
T60	Qualifier 883 894	Unexplained
T61	Qualifier 908 916	abnormal
T62	Condition 938 957	bleeding per vagina
T63	Temporal 958 964;978 997	during vaginal intercourse
T64	Temporal 968 997	following vaginal intercourse
*	OR T64 T63
T65	Procedure 1002 1022	gynaecologic surgery
T66	Temporal 1023 1057	within 90 days prior to enrollment
T67	Reference_point 1047 1057	enrollment
R27	Has_index Arg1:T66 Arg2:T67	
R28	Has_temporal Arg1:T65 Arg2:T66	
T68	Scope 958 997	during or following vaginal intercourse
*	OR T58 T62 T65
R29	Has_scope Arg1:T62 Arg2:T68	
T69	Scope 917 957	bleeding per vagina, bleeding per vagina
T70	Scope 883 916	Unexplained, undiagnosed abnormal
R30	Has_scope Arg1:T69 Arg2:T70	
T71	Condition 1078 1089	anaphylaxis
T72	Observation 1067 1074	history
T73	Condition 1100 1107	allergy
T74	Qualifier 1093 1099	severe
R31	Has_qualifier Arg1:T73 Arg2:T74	
T75	Condition 1121 1131	angioedema
T76	Observation 1138 1145	history
T77	Condition 1149 1160;1169 1177	sensitivity to latex
T78	Condition 1161 1177	allergy to latex
*	OR T78 T77
T79	Scope 1149 1177	sensitivity/allergy to latex
R32	Has_temporal Arg1:T79 Arg2:T76	
*	OR T71 T73
T80	Scope 1078 1107	anaphylaxis or severe allergy
R33	causal Arg1:T75 Arg2:T80	
R34	Has_temporal Arg1:T80 Arg2:T72	
T81	Condition 1225 1232	disease
T82	Qualifier 1213 1224	progressive
T83	Multiplier 1202 1209	chronic
T84	Temporal 1195 1200	acute
T85	Qualifier 1187 1194	serious
*	OR T82 T83 T84 T85
T86	Scope 1187 1224	serious acute, chronic or progressive
R35	Has_scope Arg1:T81 Arg2:T86	
T87	Post-eligibility 1238 1387	Any condition(s) that, in the opinion of the investigator, might interfere with adherence to study requirements or evaluation of the study objectives
T88	Subjective_judgement 1183 1232	Any serious acute, chronic or progressive disease
T89	Post-eligibility 1183 1232	Any serious acute, chronic or progressive disease
